IL17A and neoplasm: Consistent with the key roles in promoting GC tumors of IL‐17A in vivo, mice transfused with CD4+ T cells plus TCN and IL‐17A neutralizing antibody showed reduced tumor volumes as well as GC progression at every time point from day 19, when compared to mice transfused with CD4+ T cells plus TCN and control IgG (Figure 7C).